<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233766</url>
  </required_header>
  <id_info>
    <org_study_id>P02-6314</org_study_id>
    <nct_id>NCT00233766</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)</brief_title>
  <official_title>An Evaluation of Two Reduced Sirolimus Doses on the BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions(REDOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the performance and safety of two reduced sirolimus
      doses on the Bx VELOCITY Balloon-Expandable stent, mounted on the Raptor√¢ rapid exchange (RX)
      Stent Delivery System (SDS) in patients with de novo native coronary artery lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late loss measured by quantitative coronary angiography at four-months and twelve-months post-procedure.</measure>
    <time_frame>four-months and twelve-months post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH volume as measured by intravascular ultrasound (IVUS) at four-months and twelve-months post-procedure.</measure>
    <time_frame>four-months and twelve-months post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volumetric plaque burden as measured by IVUS at four-months and twelve months post-procedure.</measure>
    <time_frame>four-months and twelve months post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Four and twelve month target vessel failure (TVF).</measure>
    <time_frame>Four and twelve month</time_frame>
  </primary_outcome>
  <enrollment>60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female patient minimum 18 years of age

          2. No significant (&gt;50%) untreated stenoses proximal or distal to the target lesion that
             will not be treated during the procedure and may require revascularization or impede
             runoff;

          3. Target lesion is 18mm in length (visual estimate);

          4. Target lesion is 3.0mm and 3.5mm in diameter (visual estimate);

          5. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);

        Exclusion Criteria:

          1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the
             CK and CK-MB enzymes are back to normal;

          2. Ejection fraction 30%;

          3. Stent placement of target lesion covers a side branch &gt;2.0mm in diameter;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. E. Sousa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Nakamura M, Abizaid A, Hirohata A, Honda Y, Sousa JE, Fitzgerald PJ. Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: serial IVUS analysis of neointimal hyperplasia and luminal dimension. Catheter Cardiovasc Interv. 2007 Dec 1;70(7):946-51.</citation>
    <PMID>17621671</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>April 17, 2008</last_update_submitted>
  <last_update_submitted_qc>April 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>J. E. Sousa, MD</name_title>
    <organization>Instituto Dante Pazzanese de Cardiologia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

